Pet Pharm Biotech Co., Ltd. (TPEX:7762)
Taiwan · Delayed Price · Currency is TWD 57.70
-0.50 (-0.86%)
At close: Aug 18, 2026
Pet Pharm Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 265.54 | 222.03 | 130.7 | 117.87 | 75.74 | |
Revenue Growth | 66.98% | 69.88% | 10.89% | 55.62% | - |
Cost of Revenue | 124.94 | 105.59 | 60.74 | 53.27 | 39.88 |
Gross Profit | 140.6 | 116.44 | 69.96 | 64.59 | 35.86 |
Selling, General & Admin | 107.3 | 91.69 | 49.74 | 44.16 | 31.71 |
Research & Development | 10.76 | 10 | 12.14 | 14.05 | 7.79 |
Operating Expenses | 117.98 | 101.7 | 61.85 | 57.01 | 40.7 |
Operating Income | 22.62 | 14.74 | 8.11 | 7.59 | -4.84 |
Interest Expense | -1.44 | -0.89 | -0.18 | -0.18 | -0.2 |
Interest & Investment Income | 6.15 | 6.79 | 4.1 | 1.67 | 0.45 |
Currency Exchange Gain (Loss) | 0.04 | 0.04 | 0.23 | 0.06 | 0.12 |
Other Non Operating Income (Expenses) | 1.68 | 3.52 | 0.15 | 0.01 | 0.96 |
EBT Excluding Unusual Items | 29.05 | 24.2 | 12.42 | 9.15 | -3.5 |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.21 |
Asset Writedown | - | - | - | - | -0.1 |
Other Unusual Items | -0.03 | -0.03 | - | - | - |
Pretax Income | 29.03 | 24.17 | 12.42 | 9.15 | -3.81 |
Income Tax Expense | -0.72 | -0.72 | -2.09 | - | - |
Earnings From Continuing Operations | 29.75 | 24.9 | 14.51 | 9.15 | -3.81 |
Minority Interest in Earnings | 0.28 | 0.09 | - | - | - |
Net Income | 30.03 | 24.99 | 14.51 | 9.15 | -3.81 |
Net Income to Common | 30.03 | 24.99 | 14.51 | 9.15 | -3.81 |
Net Income Growth | 55.99% | 72.25% | 58.54% | - | - |
Shares Outstanding (Basic) | 58 | 55 | 41 | 30 | 25 |
Shares Outstanding (Diluted) | 58 | 55 | 41 | 30 | 25 |
Shares Change | 24.82% | 32.26% | 37.19% | 19.84% | - |
EPS (Basic) | 0.52 | 0.46 | 0.35 | 0.30 | -0.15 |
EPS (Diluted) | 0.51 | 0.45 | 0.35 | 0.30 | -0.16 |
EPS Growth | 24.29% | 28.44% | 17.07% | - | - |
Free Cash Flow | 44.22 | 4.79 | -159.51 | 8.08 | -27.87 |
Free Cash Flow Per Share | 0.76 | 0.09 | -3.85 | 0.27 | -1.11 |
Dividend Per Share | 0.246 | 0.246 | 0.089 | 0.194 | - |
Dividend Growth | 177.68% | 177.68% | -54.37% | - | - |
Gross Margin | 52.95% | 52.44% | 53.53% | 54.80% | 47.34% |
Operating Margin | 8.52% | 6.64% | 6.21% | 6.44% | -6.39% |
Profit Margin | 11.31% | 11.25% | 11.10% | 7.76% | -5.03% |
Free Cash Flow Margin | 16.65% | 2.16% | -122.05% | 6.85% | -36.80% |
EBITDA | 57.15 | 38.19 | 19.45 | 18.75 | 5.89 |
EBITDA Margin | 21.52% | 17.20% | 14.88% | 15.91% | 7.78% |
D&A For EBITDA | 34.53 | 23.45 | 11.34 | 11.17 | 10.73 |
EBIT | 22.62 | 14.74 | 8.11 | 7.59 | -4.84 |
EBIT Margin | 8.52% | 6.64% | 6.21% | 6.44% | -6.39% |